Mylan inks $465m settlement with DOJ over EpiPen Medicaid classification

Mylan (NSDQ:MYL) said today that it inked a $465 million deal with U.S. Dept. of Justice to settle claims that it misclassified its EpiPen allergy auto-injector device with the Medicaid Drug Rebate Program.
In October last year, The Centers for Medicare & Medicaid Services said that Mylan had been overcharging Medicaid for its EpiPen device for years, despite being warned that it should have paid bigger rebates.
Get the full story at our sister site, Drug Delivery Business News.
The post Mylan inks $465m settlement with DOJ over EpiPen Medicaid classification appeared first on MassDevice.

Source: Mass Device - August 17, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Legal News Pharmaceuticals Wall Street Beat Centers for Medicare and Medicaid Services (CMS) Mylan Source Type: news